A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Trial Profile

A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Alalevonadifloxacin (Primary)
  • Indications Liver disorders
  • Focus Pharmacokinetics
  • Sponsors Wockhardt
  • Most Recent Events

    • 12 Apr 2016 Results evaluating the PK and safety of WCK 2349 presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
    • 24 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top